Mais les résultats doivent être attendus longtemps et il n'y a généralement pas de temps metronidazole prix L'autre cas, c'est que l'achat d'un ou d'un autre antibiotique dans une pharmacie classique nécessite des dépenses matérielles considérables et pas toutes les personnes ne peuvent acheter des produits pharmaceutiques aussi coûteux.

Microsoft word - hoofdstuk 11.doc

11 Spastische verlamming, slappe verlamming, contractuurvorming Literatuur Abel NA, Smith RA. Intrathecal baclofen for intractable spinal spasticity. Arch Phys Med Alfieri V. Electrical treatment of spasticity. Scand J Rehabil 1982: 14: 177-82. Azouvi P, Mane M, Thiebaut JP, Denys P, Remy-Neris O, Bussel B. Intrathecal Administration for Control of Severe Spinal Spasticity. Functional Improvement and Long-Term Follow-Up. Arch Phys Med Rehabil 1996; 75: 35-9. Basmaijan JV. Super G. Dantrolene Sodium in the treatment of spasticity. Arch Phys Med Basmaijan JV, Yucel V. Effects of a GABA-derivative (BA-34647) on spasticity. Am J Phys Beckers DML, Buck MJI, Pons C. De revalidatie van dwarslaesiepatiënten. Lochem: De Bohannon RW, Larkin PA. Cybex II isokinetic dynamometer for the documentation of Bohannon RW, Smith MB. Interrator of a modified Ashworth Scale of muscle spasticity. Brattstrom M, Moritz U, Svantesson G. Electromyographic studies of peripheral nerve block with phenol. Scand J Rehabil Med 1970; 2: 17-22. Brown P. Pathofysiology of spasticity [Editorial]. J Neurol Neurosurg Psychiatry 1994; 57: Cava TJ. Botulinum toxin management of spasticity in upper motor neuron lesions. Eur J Davidoff RA. Mode of action of antispasticity drugs. Neurosurgery: State of the art Davies J. Selective depression of synaptic transmission of spinal neurons in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiodazole (DS103-282). Br J Pharmacol 1982; 76: 483. Delwaide PJ. Electrophysiological analysis of the mode of action of muscle relaxants in Douglas AF, Weiner HL, Schwartz DR. Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. J Neurosurg 2005; 102: 1133-6. Gans MB, Glenn MB. Introduction. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. Gantmacher J. Oral vs intrathecal baclofen. Toxicity of baclofen. Interventional Spasticity Therapies workshop. European Continuing Medical Training. Genk; 1996. Goff B. Grading of spasticity and its effect on voluntary movement. Physiotherapy 1976; Gottlieb GL, Atarwal GC, Penn R. Sinusoidal oscillation of the ankle as a means of evaluating the spastic patiënt. J Neurol Neurosurg Psychiatry 1978; 41: 32. Gottlieb GL, Myklebust BM, Stefoski D et al. Evaluation of cervical stimulation for chronic treatment of spasticity. Neurology 1985; 35: 699-704. Granger CV et al. Advances in functional assessment for medical rehabilitation. Top Haley SM, Inacio CA. Evaluation of spasticity and its effect on motor function management. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger;1990. 70-96. Halpern D et al. Muscular hypertonia. Quantitative analysis. Arch Phys Med Rehabil 1979; Halpern D. Histologic studies in animals after intramuscular neurolysis with phenol. Arch Hermens HJ. Surface Emg, PH.D.-Thesis. Journal of Rehabilitation Sciences 1992; 3: 90- Illis LS. Management of Spasticity. Neurological Rehabilitation. Oxford: Blackwell Jones RF, Burke D, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry 1970; 33: 464. Katz RT. Management in spasticity. In: Braddom RL, editor. Physical Medicine & Rehabilitation. Philadelphia: Saunders Company; 1996. 581-604. Katz RT. Spasticity. In: O`Young B, Young MA, Stiens SA, editors. PM & R Secrets. Katz RT, Rymer WJ. Spastic hypertonia. Mechanisms and measurement. Arch Phys Med Khalili AA, Harmel MH, Forster S, Benton JG. Mangement of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964: 45: 513-9. Knutsson E. Quantification of spasticity. In: Strappler A, Weindl A, editors. Electromyography and Evoked potentials. Berlin: Springer-Verlag; 1985. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity. Disordered motor control. Chicago: Chicago Yearbook Medical Publications; 1980. 485-94. Maynard FM. Early clinical experience with clonidine in spinal spasticity. Paraplegia 1986; McLean BN. Intrathecal baclofen in severe spasticity. British Journal of Hospital Medicine Merrit JL. Management of spasticity in spinal cord injury. Mayo Clin Proc 1981; 56: 614- Michaelis LS. Spasticity in spinal cord injuries. In: Vinken PJ, Bruyn GW, editors. Handbook of Clinical Neurology. Amsterdam; 1976. 447-87. Middleton JW, Siddall PJ, Walker S. Intrathecal Clonidine and Baclofen in the Management of Spasticity and Neuropathic Pain Follwing Spinal Cord Injury. A Case Study. Arch Phys Med Rehabil 1996; 77: 824-6. Millet MF, Mortamais J, Sindou M et al. In: Simon L, editor. Actualité en Reeducation fonctionelle et readaptation. Paris: Masson; 1981. 76-85. Moore AP. General and clinical aspects of treatment with botulinum toxin. In: Moore P, editor. Handbook of botulinum toxin treatment. Oxford: Blackwell Science; 1995. Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc. J 1985; Oosterhuis HJGH. Klinische neurologie. 11e ed. Houten: Bohn Stafleu van Loghum; Penn RD, Kroin JS. Continuous intrathecal Baclofen for severe spasticity. Lancet 1985; Penn RD, Kroin JS. Intrathecal Baclofen alleviates spinal cord spasticity. Lancet 1984; 1: Petrillo CR, Chu DS, Davis SW. Phenol block on the tibial nerve in the hemiplegic patiënt. Pirotte B, Wesel P, Heilporn A, Brotchi J. Clinical assessment of severe spasticity. Interventional Spasticity Therapies workshop. European Continuing Medical Training. Genk; 1996. Priebe MM, Sherwood AM, Graves DE. Effectiveness of gabapentin in controlling spasticity. A quantitative study. Spinal Cord 1997; 35: 171-5. Priebe MM, Sherwood AM, Thonby JI, Kharas NF, Markowski J. Clinical Assessment of Spasticity in Spinal Cord Injury. A Multidimensional Problem. Arch Phys Med Rehabil 1996; 77: 713-6. Satkunam LE. Rehabilitation medicine. 3. Management of adult spasticity. Review. Can Stein AB, Pomerantz F, Schechtman J. Evaluation and Management of spasticity in Spinal Cord Injury. Top Spinal Cord Inj Rehabil 1997; 70-83. Voth EA, Schwartz RH. Medicinal applications of Delta-9-Tetrahydrocannabinol and Marijuana. Ann Intern Med 1997; 126: 791-8. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994; 44 Suppl 9: S60-S69. Wartenberg R: Pendulousness of the legs as a diagnostic test. Neurology 1951; 1: 18. Whitlock JA. Neurophysiology of spasticity. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. 8-33. Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. 1-7. Young RR, Shahani BT. Spasticity in Spinal Cord Injured Patients. In: Bloch RF, Basbaum M, editors. Management of Spinal Cord Injuries. Baltimore: Williams & Wilkins; 1986. 241-83.

Source: http://www.nvdg.org/pdf/handboek/Hoofdstuk%2011.pdf

Doctors assail growing use of antipsychotic drugs for dementia - nytimes.com

Doctors Assail Growing Use of Antipsychotic Drugs for Dement. http://www.nytimes.com/2008/06/24/health/24deme.html?page. June 24, 2008 Doctors Say Medication Is Overused in DementiaBy LAURIE TARKAN Correction Appended Ramona Lamascola thought she was losing her 88-year-old mother to dementia. Instead, shewas losing her to overmedication. Last fall her mother, Theresa Lamascola, of the

Microsoft word - topamax consent.doc

Topamax (topiramate) General Information Weight No More – Effective, physician-supervised weight-management solutions Main Indication For Use: Migraine prevention and as adjunctive therapy in children and adults with partial onset seizures or primary generalized tonic-clonic seizures. Side Effects: Most common and not dose related were somnolence (sleepiness,)

Copyright ©2010-2018 Medical Science